News
Obsidian Therapeutics to Present OBX-115 Phase 2 Clinical Data in Advanced Melanoma in Oral Presentation at 2026 ASCO Annual Meeting
April 21, 2026
Read More
Obsidian Therapeutics and Galera Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement
April 14, 2026
Read More
ABOUT US
We are pioneers in cell and gene therapy
Leading the next generation of engineered therapeutics
Our Platform
Our proprietary
cytoDRiVE platform
Leverages drug responsive domains (DRDs) to control protein function using an FDA-approved small molecule
OBSIDIAN CAREERS
Join Our Team
Join our collaborative team of innovators who are motivated by a sense of urgency to help patients in need.
Our collective knowledge, capabilities, intellect and energy is our greatest strength.